HomeStock ScreenerConcord BiotechIntrinsic Value

Concord Biotech Intrinsic Value

Concord Biotech (CONCORDBIO) median intrinsic value is ₹2383.40 from 10 valuation models (range ₹410–₹3413), vs current price ₹1365.00 — +74.6% upside (Trading Below Calculated Value), margin of safety 42.7%. Analyse Concord Biotech shareholding analysis to track promoter, FII and institutional holdings.

Current Stock Price
₹1365.00
Primary Intrinsic Value
₹744.48
Market Cap
₹1502 Cr
+74.6% Upside
Median Value
₹2383.40
Value Range
₹410 - ₹3413
Assessment
Trading Below Calculated Value
Safety Margin
42.7%

CONCORDBIO Valuation Methods Summary — DCF, Graham Number & P/E

Concord Biotech intrinsic value across 10 models vs current price ₹1365.00 — upside/downside and value range per method. Read CONCORDBIO dividend payout details for the complete payout history and dividend yield track record.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹744.48 ₹595.58 - ₹893.38 -45.5% EPS: ₹33.84, Sector P/E: 22x
Book Value Method asset ₹3412.50 ₹3071.25 - ₹3753.75 +150.0% Book Value/Share: ₹1831.82, P/B: 2.0x
Revenue Multiple Method revenue ₹2480.00 ₹2232.00 - ₹2728.00 +81.7% Revenue/Share: ₹1240.00, P/S: 2.0x
EBITDA Multiple Method earnings ₹2730.00 ₹2457.00 - ₹3003.00 +100.0% EBITDA: ₹536.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹2383.40 ₹1906.72 - ₹2860.08 +74.6% CF Growth: 6.4%, Discount: 15%
PEG Ratio Method growth ₹409.50 ₹368.55 - ₹450.45 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹522.83 ₹470.55 - ₹575.11 -61.7% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹2730.00 ₹2457.00 - ₹3003.00 +100.0% ROE: 17.7%, P/E Multiple: 14x
Graham Defensive Method conservative ₹1180.99 ₹1062.89 - ₹1299.09 -13.5% EPS: ₹33.84, BVPS: ₹1831.82
Dividend Yield Method dividend ₹409.50 ₹368.55 - ₹450.45 -70.0% DPS: ₹7.55, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

CONCORDBIO Intrinsic Value vs Market Price — All Valuation Models

Concord Biotech fair value range ₹410–₹3413 vs current market price ₹1365.00 across 10 valuation models. For current market price and key ratios, visit Concord Biotech stock price NSE.

CONCORDBIO Intrinsic Value Analysis — Undervalued or Overvalued?

Concord Biotech median intrinsic value ₹2383.40, current price ₹1365.00 — Trading Below Calculated Value by 74.6%, margin of safety 42.7%.

What is the intrinsic value of CONCORDBIO?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Concord Biotech (CONCORDBIO) is ₹2383.40 (median value). With the current market price of ₹1365.00, this represents a +74.6% variance from our estimated fair value.

The valuation range spans from ₹409.50 to ₹3412.50, indicating ₹409.50 - ₹3412.50.

Is CONCORDBIO undervalued or overvalued?

Based on our multi-method analysis, Concord Biotech (CONCORDBIO) appears to be trading below calculated value by approximately 74.6%.

CONCORDBIO Financial Health — Key Ratios vs Industry Benchmarks

Concord Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Current Ratio 24.51 Industry Standard: 2.0+ Above 2.0 Measures short-term liquidity capacity
Return on Equity 17.7% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 36.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 0.61x Industry Standard: 1.0x+ Above 0.5x Measures asset utilization efficiency

CONCORDBIO Cash Flow Quality — Operating & Free Cash Flow

Concord Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹267 Cr ₹196 Cr Positive Free Cash Flow 8/10
March 2025 ₹245 Cr ₹165 Cr Positive Free Cash Flow 8/10
March 2024 ₹266 Cr ₹189 Cr Positive Free Cash Flow 8/10
March 2023 ₹246 Cr ₹167 Cr Positive Free Cash Flow 8/10
March 2022 ₹208 Cr ₹152 Cr Positive Free Cash Flow 8/10